Dr. Lior Shaltiel reports

NUREXONE DEMONSTRATES EXTENDED THERAPEUTIC WINDOW OF EXOPTEN POST SPINAL-CORD INJURY IN PRECLINICAL STUDY

Nurexone Biologic Inc. has released compelling new findings that highlight the therapeutic potential of ExoPTEN for patients with spinal cord injuries. In a recent preclinical study using a spinal cord compression model, its team demonstrated that ExoPTEN has a strong ability to target and accumulate at the injury site, even when administered up to one week after the injury occurred. This finding is crucial because it suggests a long window of time in which treatment can be effectively administered.

Dr. Lior Shaltiel, Nurexone chief executive officer, emphasized the real-world significance of this capability by stating: "The ability to treat patients up to seven days postinjury could broaden the range of patients eligible for treatment and extend the window of effectiveness, leading to enhanced recovery. Moreover, the findings can enhance significantly the ability to recruit more patients to clinical trials and to expand the numbers of treatable patients, without being limited by a short therapeutic window and hospital administration challenges."

He continued, "With the global incidence of spinal cord injury estimated between 250,000 and 500,000 cases annually and given that some patients do not receive immediate treatment, the potential market for a therapy effective up to one-week postinjury could be substantial."

The ExoPTEN was labelled with a fluorescent mark and administered to rats with induced spinal cord compression injuries. The administration was conducted at four different time points: on the day of injury (day 0), three days later, five days later and seven days later, and compared with each other and to an untreated control group. The goal was to evaluate how well ExoPTEN targets and accumulates at an injury site over time.

Using an advanced in vivo imaging system, it was observed that ExoPTEN consistently accumulated at the injury site. A notable gradient of homing capacity was observed, with later administration times resulting in progressively higher levels of accumulation. The highest accumulation was seen in those treated seven days postinjury with a statistically significant dose-dependent accumulation of ExoPTEN at the injury site.

These results underscore the exceptional homing capacity of ExoPTEN, even seven days postinjury, suggesting a broad therapeutic window for intervention. This creates new possibilities for the timing and flexibility of treatment, enhancing the potential for recovery in patients with spinal cord injuries.

Dr. Noa Avni, director of research and development, stated: "We are excited about the implications of these findings for our phase 1/2 clinical trial design and patient care. The extended therapeutic window we have demonstrated not only highlights the potency of our exosome-based therapy but also offers hope for adaptable treatment regimens in clinical settings."

About Nurexone Biologic Inc.

Nurexone is a TSX Venture Exchange- and OTCQB-listed pharmaceutical company that is developing a platform for biologically guided exosome-based therapies to be delivered, non-invasively, to patients who have suffered central nervous system injuries. The company's first product, ExoPTEN for acute spinal cord injury, was proved to recover motor function in 75 per cent of laboratory rats when administered intranasally. ExoPTEN has been granted orphan drug designation by the Food and Drug Administration. The Nurexone platform technology is expected to offer novel solutions to drug companies interested in non-invasive targeted drug delivery for other indications.

We seek Safe Harbor.